Trial Profile
protocol H8D-MC-EMBH PPAR Alpha (LY518674): a phase 2 dose-response study to evaluate the blood pressure-lowering effect in essential hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs LY 518674 (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 06 May 2007 Status changed from suspended
- 14 Dec 2006 New trial record.